BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Ridaforolimus (Primary) ; Zotarolimus
- Indications Coronary artery restenosis; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms BIONICS
- Sponsors Medinol
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Planned End Date changed from 1 Aug 2020 to 1 Nov 2021.
- 14 Apr 2020 Results of subgroup analysis published in the American Journal of Cardiology